Thursday, July 24, 2025

 

When dreams turn dark: Neuroscientists to study nightmares and mental health







Penn State
Researchers lead project to gain insight into the purpose of dreams 

image: 

Nanyin Zhang, the Dorothy Foehr Huck and J. Lloyd Chair in Brain Imaging and professor of biomedical engineering, of electrical engineering and of engineering science and mechanics; Patrick Drew, professor of engineering science and mechanics, of biomedical engineering, of neurosurgery and of biology; and Nikki Crowley, associate professor of biology and of biomedical engineering, Huck Early Career Chair in Neurobiology and Neural Engineering and director of the Penn State Neuroscience Institute at University Park, received a three-year, $1.2 million grant from the W.M. Keck Foundation to gain insight into the purpose of dreams. 

view more 

Credit: Keith Hickey/Penn State




UNIVERSITY PARK, Pa. — Dreams, and likely nightmares, are experienced universally across humans and animals, but neuroscientists still do not know why. Now, with a three-year, $1.2 million grant from the W.M. Keck Foundation, an interdisciplinary team of researchers at Penn State will study the underlying mechanisms of nightmares and their relationship with anxiety-related mental health disorders, such as post-traumatic stress disorder (PTSD).  

The team aiming to expand the scientific understanding of nightmares includes principal investigator Patrick Drew, professor of engineering science and mechanics at Penn State; and co-principal investigators Nikki Crowley, associate professor of biology and of biomedical engineering, Huck Early Career Chair in Neurobiology and Neural Engineering and director of the Penn State Neuroscience Institute at University Park; and Nanyin Zhang, the Dorothy Foehr Huck and J. Lloyd Chair in Brain Imaging and professor of biomedical engineering, of electrical engineering and of engineering science and mechanics. 

“To me, the exciting thing about this research is that we now have a way to gain insight into the purpose of dreams,” said Drew, who also has affiliations with the biomedical engineering, neurosurgery and biology departments at Penn State. “The question of why we dream has puzzled mankind for millennia, and by looking at what changes in neural circuits and behaviors nightmares cause, we hope to be able to figure out the biological purpose of dreaming.” 

To investigate the neural mechanics of nightmares, the researchers will rely on the side effects of the drug mefloquine, which was once used by American soldiers as a disease preventative during deployments to Somalia, Afghanistan and Iraq. Though effective in preventing malaria, the drug is no longer prescribed due its serious neurological side effects, including inducing nightmares. The researchers will test mice treated with the drug for two weeks while monitoring them for unusual behaviors.  

“In the past, it has been hard to study dreams, because it is hard to determine what is a regular dream state and what is a nightmare,” Zhang said.  

Led by Drew, researchers will use novel imaging techniques to map the mice’s facial expressions and pupil sizes to know which sleep stage they are in. The team will also use functional magnetic resonance imaging (fMRI), led by Zhang, and calcium signal recording, led by Drew, to record the specific neuron type that might be underlying the dream or nightmare.  

Through the various imaging methods and behavioral observations, researchers will record what is happening within the animals’ brains at each sleep stage, including rapid eye movement and non-rapid eye movement stages. The researchers, led by Crowley, will also monitor the neurotransmitters and neuromodulators in two regions of the brain, the prefrontal cortex and amygdala, to understand how these systems are disrupted during nightmares. Through these observations, the researchers said they hope to determine if there is an indication of nightmares having a relationship with mental health disorders, like PTSD.  

“Most people believe that nightmares are a consequence of having PTSD, but there is also the possibility that nightmares could exacerbate symptoms or even cause the presence of mental disorders,” Zhang explained.  

Using the mice as a model, the researchers said they plan to develop a framework to predict the onset of mental health disorders, such as anxiety, due to the presence or absence of nightmares. If successful, their model could lead to sleep intervention-based treatments for people suffering with these conditions, according to the researchers.  

“Penn State is distinctively suited to carry out this research, both in the capabilities of our team and in possessing the resources and intellectual space for a high-risk question like this one,” Crowley said. “Our post-docs and grad students, in particular, have an opportunity to contribute to a fascinating philosophical and biological research question that very few scientists will ever get to work on in their entire career.”  

The W. M. Keck Foundation was established in 1954 by oil company founder William Myron Keck. As a philanthropic institution, the foundation supports discoveries in science, engineering and medical research that are distinctive or novel in their approach or promise to develop new technologies, instrumentation or methods. This award is the first W. M. Keck Foundation grant directed to Penn State in almost 25 years.  





 

New research supports Ivermectin as an effective strategy to control malaria transmission



The BOHEMIA trial in Kenya showed a 26% reduction in new malaria infections among children aged 5-15



Barcelona Institute for Global Health (ISGlobal)

Ivermectin tablets 

image: 

Ivermectin tablets used for the BOHEMIA trial in Kenya

view more 

Credit: Life Spark Studios/BOHEMIA project





Ivermectin administered to the whole population significantly reduces malaria transmission, offering new hope in the fight against the disease. The BOHEMIA trial, the largest study on ivermectin for malaria to date, showed a 26% reduction in new malaria infection on top of existing bed nets, providing strong evidence of ivermectin’s potential as a complementary tool in malaria control. The results of this project, coordinated by the Barcelona Institute for Global Health (ISGlobal) -an institution supported by the “la Caixa” Foundation- in collaboration with the Manhiça Health Research Centre (CISM) and the KEMRI-Wellcome Trust Research Programme, have been published in The New England Journal of Medicine.    

Malaria remains a global health challenge, with 263 million cases and 597,000 deaths reported in 2023. Current vector control methods, such as long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS), have become less effective due to insecticide resistance and behavioural adaptations in mosquitoes to bite outdoors and during dusk or dawn, when people are not protected by these measures. This underscores the urgent need for innovative solutions to combat malaria.

Ivermectin for malaria: A novel strategy

Ivermectin, a drug traditionally used to treat neglected tropical diseases like onchocerciasis, which causes river blindness, and lymphatic filariasis, which causes elephantiasis, has been shown to reduce malaria transmission by killing the mosquitoes that feed on treated individuals. Given the rising resistance to conventional insecticides, ivermectin could offer an effective new approach to tackle malaria transmission, especially in regions where traditional methods have become less effective.

The Unitaid-funded BOHEMIA project (Broad One Health Endectocide-based Malaria Intervention in Africa) conducted two Mass Drug Administration (MDA) trials in the high-burden malaria regions: Kwale County (Kenya) and Mopeia district (Mozambique). The trials assessed the safety and efficacy of a single monthly dose of ivermectin (400 mcg/kg) given for three consecutive months at the start of the rainy season in reducing malaria transmission. In Kenya, the intervention targeted children aged 5–15, while in Mozambique it focused on children under five.

Malaria reduction in Kenya

In Kwale County, Kenya, children who received ivermectin experienced a 26% reduction in malaria infection incidence compared to those who received albendazole, the control drug used in the study. The trial involved over 20,000 participants and more than 56,000 treatments, demonstrating that ivermectin significantly reduced malaria infection rates—particularly among children living further from cluster borders or in areas where drug distribution was more efficient. Moreover, the safety profile of ivermectin was favourable, with no severe drug-related adverse events and only mild, transient side effects already seen with ivermectin in campaigns against neglected tropical diseases.

“We are thrilled with these results”, says Carlos Chaccour, co-principal investigator of the BOHEMIA project and ISGlobal researcher at the time of the study. “Ivermectin has shown great promise in reducing malaria transmission and could complement existing control measures. With continued research, ivermectin MDA could become an effective tool for malaria control and even contribute to elimination efforts,” Chaccour, who is now a researcher at the Navarra Centre for International Development at the University of Navarra, adds. 

“These results align with the World Health Organization’s (WHO) criteria for new vector control tools”, states Joseph Mwangangi, from the KEMRI-Wellcome Trust Research Programme. “The findings suggest that ivermectin MDA could be a valuable complementary strategy for malaria control, particularly in areas where mosquito resistance to insecticides is a growing concern”, adds Marta Maia, BOHEMIA’s lead entomologist from the University of Oxford.

Lessons from the Mozambique trial

In contrast, the implementation of the Mozambique trial in the rural district of Mopeia faced severe disruptions due to Cyclone Gombe (2022) and a subsequent cholera outbreak, which significantly disrupted operations. “One of the most important lessons we learned from the trial in Mopeia is that strong community engagement is essential,” states Francisco Saúte, director of the Manhiça Health Research Centre (CISM). “Building trust with local communities and fostering close collaboration with the Health Ministry, National Malaria Control Program, and local authorities was key to ensuring acceptance of the ivermectin MDA.”

Expanding the Impact Beyond Malaria

In addition to reducing malaria transmission, ivermectin MDA offers significant collateral benefits. The BOHEMIA team found an important reduction in the prevalence of skin infestations such as scabies and head lice in the ivermectin group in Mozambique, and the community reported a major reduction in bed bugs in Kenya. These effects are particularly valuable when ivermectin is integrated into existing delivery systems, maximising its impact on public health.

Shaping the future of malaria prevention

The study is part of a larger global effort to assess ivermectin’s potential in malaria control. The findings have been reviewed by the WHO vector control advisory group, which concluded that the study had demonstrated impact and recommended further studies. Findings were also shared with national health authorities as they evaluate the potential inclusion of ivermectin in malaria control programmes.

“This research has the potential to shape the future of malaria prevention, particularly in endemic areas where existing tools are failing”, concludes Regina Rabinovich, BOHEMIA PI and Director of ISGlobal’s Malaria Elimination Initiative. “With its novel mechanism of action and proven safety profile, ivermectin could offer a new approach using a well-known, safe drug that can add to the effect of other mosquito control tools available today.”

 

Can Amazon Alexa or Google Home help detect Parkinson’s?



A quick, speech-based AI tool offers a new way to screen for a key indicator of the neurodegenerative disease.



University of Rochester





Computer scientists at the University of Rochester have developed an AI-powered, speech-based screening tool that can help people assess whether they are showing signs of Parkinson’s disease, the fastest growing neurological disability in the world. A study published in the journal npj Parkinson’s Disease introduces a web-based screening test that asks users to recite two pangrams—short sentences using all 26 letters of the alphabet. Within seconds, the AI analyzes the voice recordings for subtle patterns linked to Parkinson’s, with nearly 86 percent accuracy.

Parkinson’s disease is typically diagnosed by movement disorder specialists—neurologists with specific training to evaluate complex motor symptoms—using a combination of family history, neurological examinations, and brain imaging. While the study’s authors emphasize that their AI-based tool is not a substitute for a clinical diagnosis, they see it as a fast, low-barrier, and accessible way to flag people, especially in remote areas, who might be living with the condition and encourage them to seek more thorough clinical evaluations.

“There are huge swaths of the US and across the globe where access to specialized neurological care is limited,” says Ehsan Hoque, a professor in Rochester’s Department of Computer Science and co-director of the Rochester Human-Computer Interaction Laboratory. “With users’ consent, widely used speech-based interfaces like Amazon Alexa or Google Home could potentially help people identify if they need to seek further care.”

To train and validate the tool, the researchers collected data from more than 1,300 participants—with and without Parkinson’s—across diverse environments, including home settings, clinical visits at the University of Rochester Medical Center, and the InMotion Parkinson’s disease care center in Ohio.

Using the computer’s microphone, users simply read aloud two sentences: “The quick brown fox jumps over the lazy dog. The dog wakes up and follows the fox into the forest, but again the quick brown fox jumps over the lazy dog.” By leveraging the power of advanced semi-supervised speech models trained on millions of digital audio recordings to understand the characteristics of speech, the tool can glean enough vocal cues from those two short sentences to flag warning signs.

“These large audio models are trained to understand how speech works; for example, the way someone with Parkinson’s would utter sounds, pause, breathe, and inadvertently add features of unintelligibility is different in someone without Parkinson’s,” says Abdelrahman Abdelkader, a computer science master’s degree student in Hoque’s lab and one of the two lead authors of the study. “If a person is saying the pangram that contains the full spectrum of the alphabetical variability and trails off at certain points, the model can tell if that’s different from the typical representation and flag it.”

The tool was 85.7 percent accurate when tested, providing a strong indication of whether someone may have Parkinson’s. But it is a multifaceted disease, and while some people demonstrate symptoms through speech, they can also display signs through motor tasks or facial expressions. Over the last decade, Hoque’s lab has pursued clever algorithms to combine multiple indicators and produced state-of-the-art results.

“Research shows that nearly 89 percent of people with Parkinson’s have a deformity in their voice that can be indicative of the disease, making speech a strong starting point for digital screening,” says Tariq Adnan, a computer science PhD student affiliated with Hoque’s lab and another lead author of the study. “By combining this method with assessments of other symptoms, we aim to cover the majority of people through our accessible screening process.”

An interactive demo of the lab’s three screening tests, including the speech test outlined in the paper, is available online.

The other authors of the paper include PhD students Md. Saiful Islam, who co-supervised the work with Hoque, Zipei Liu, Ekram Hossain, and Sooyong Park.

The study was funded by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, the Gordon and Betty Moore Foundation, a Google Faculty Research Award, and a Google PhD Fellowship.

 

New research reveals scars of Gambia’s witch hunts



UN-backed study shows lasting damage caused by state-led witchcraft accusations



Anglia Ruskin University





A new United Nations-funded study has highlighted the lasting psychological and social scars left by a state-sponsored witch hunt in The Gambia, more than a decade after it was carried out by former President Yahya Jammeh.

The research, led by Professor Mick Finlay of Anglia Ruskin University (ARU) in collaboration with the University of The Gambia and Nottingham Trent University, is the first academic study into the stigma associated with government-led witchcraft accusations, and includes interviews with victims and their families from the villages most affected by the campaign.

Jammeh’s 22-year dictatorship, which ended in 2016, was marked by human rights abuses including torture, extrajudicial killings and disappearances. Between 2008-2009, he orchestrated a campaign of witch hunts focusing on the West Coast and North Bank regions. These were led by a group of “witch hunters” from neighbouring countries, supported by The Gambia’s security forces.

Hundreds of people, mainly elderly, were detained, beaten, raped and subjected to degrading treatment. It is thought 41 people died and the survivors faced social exclusion and discrimination when they returned home because of the stigma associated with the witchcraft accusations.

The new study, published in the Journal of Community and Applied Social Psychology and funded by the United Nations Development Program (The Gambia), involved interviewing and surveying the victims and their families, as well as members of their communities.

There was widespread sympathy for those affected – 98% of survey respondents expressed compassion for victims and their families – and a high level of agreement that the government (99%) and the community (92%) should provide more help for victims, indicating that the effects of the witch hunts were still being experienced.

The study also highlighted the complex role of traditional beliefs in perpetuating stigma. Although most participants believed the witch hunts were organised to frighten people not to oppose President Jammeh (89%) or to sow division (87%), 25% believed the threat from witches was real, including 22% of victims and the families of victims surveyed.

However, there was overwhelming support for legal reform. Almost all participants agreed that accusations of witchcraft should be made illegal (98%), and those responsible should be punished (95%).

Through interviews, the researchers found that the stigma extended beyond individuals to their families and entire villages. Children of victims were bullied at school, families were shunned, and some communities were labelled as “witch villages” by neighbouring areas. This led to broken relationships, mistrust and long-lasting divisions within and between communities.

Victims reported a range of psychological conditions including anxiety, panic attacks and post-traumatic symptoms. Many described feeling powerless and socially isolated. Some withdrew from public life entirely, while others struggled to find work.

Although The Gambia’s current government established a Truth, Reconciliation and Reparations Commission (TRRC) to investigate the human rights abuses carried out by Jammeh, the study found many victims felt more needed to be done to address the specific harms caused by the witch hunts.

Participants proposed a range of measures to support reconciliation and healing including public declarations of innocence, legal reforms to criminalise witchcraft accusations, counselling, educational support, financial reparations and community-led dialogues to restore victims’ reputations.

Mick Finlay, the lead author of the study and Professor of Social and Applied Psychology at Anglia Ruskin University (ARU), said: “Our extensive fieldwork showed that not only did victims of the witchcraft accusations have to deal with the trauma of the human rights abuses, they also experienced a range of longer-term stigmatising effects from sections of their communities.

“There was a strong desire among those we spoke to for official recognition of the injustice they suffered. Addressing the stigma of Jammeh’s witch hunts involves restoring the good name of the victims through official declarations as well as rebuilding their social roles and relationships.

“Although The Gambia is undergoing transitional justice processes to address the impacts of the dictatorship, the recommendations by the participants should help the government and NGOs to further develop reparation and reconciliation processes related to the specific case of state-sanctioned witch hunts.

“Our findings will be of interest to other countries going through transitional justice processes when human rights come into conflict with traditional beliefs, especially belief in witchcraft.”

The open access study also involved the Women's Association of Victims' Empowerment (WAVE) charity in The Gambia and is published by the Journal of Community and Applied Social Psychology.

 

Wednesday, July 23, 2025

 

Study shows a need for vigilance when observing long COVID symptoms in younger children



Rutgers researchers say clinicians and caregivers may not recognize the symptoms because they are unfamiliar with it



Rutgers University





Infants, toddlers and preschoolers exhibit symptoms of long COVID, but the symptoms can be different and more difficult to identify in these children, according to Rutgers Health research.   

The new study is part of the National Institutes of Health–funded Researching COVID to Enhance Recovery (RECOVER) initiative and published in the Journal of the American Medical Association Pediatrics

Lawrence Kleinman, a professor and vice chair of the Department of Pediatrics at Rutgers Robert Wood Johnson Medical School and a professor of global public health at Rutgers School of Public Health, is the lead investigator for the Collaborative Long-term study of Outcomes of COVID-19 in Kids (CLOCK), a national consortium led by Rutgers.

“The COVID pandemic began with a myth – that children are spared its ill effects. In contrast, many children were sick with COVID, and we now have a new chronic illness emerging,” Kleinman said. “We are working hard to characterize long COVID in children and it will be critical for policymakers to assure that we have adequate resources to support and manage these children now and in the future.”

Of the total 1,011 children included in the study, 472 were infants and toddlers (children 2 years old or younger) and 539 were preschoolers (children 3 to 5 years old). Overall, 101 (15%) of the 677 children with previous SARS-CoV-2 infection were identified as likely having long COVID. The symptoms of long COVID in these age groups differ from those reported among school age children and teens. Infants and toddlers with long COVID were more likely to experience difficulty sleeping, fussiness, poor appetite, stuffy nose and coughing while preschoolers were more likely to experience coughing and daytime tiredness and low energy.

Researchers said they can confirm that younger children can have long COVID. Clinicians and caregivers may not recognize long COVID in these children because they are unfamiliar with it. The authors explain too that the inability of younger children to describe how they feel may make identification of long COVID more difficult in this age group. For similar reasons it is important for pediatricians and family physicians to consider long COVID when children present with the symptoms described. The failure to diagnose long COVID quickly delays treatment and inhibits availability of supportive services to children with long COVID.

“This study is the largest systematic look at long COVID in younger children in the United States,” said Sunanda Gaur, a professor of pediatrics and director of the Adult and Pediatric Clinical Research Centers at Robert Wood Johnson University Hospital. “It suggests that this is an illness that children, families, pediatricians and the health care and educational system will be dealing with for a generation.”

+++

About RECOVER: The National Institutes of Health Researching COVID to Enhance Recovery (NIH RECOVER) Initiative is a $1.15 billion effort, which is supported in part through the American Rescue Plan Act of 2021. It seeks to identify how people recuperate from COVID-19 and who is at risk for developing post-acute sequelae of SARS-CoV-2 (PASC). Researchers also are working with patients, clinicians and communities across the United States to identify strategies to prevent and treat the long-term effects of COVID, including long COVID. For more information, please visit recovercovid.org.   

 

Long COVID Pediatric Awareness Week is July 21 to July 25, 2025, and is hosted by Long COVID Families.org.